Trials / Not Yet Recruiting
Not Yet RecruitingNCT06747936
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients with Primary Hypercholesterolemia.
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-2281 | PO, Once daily, 8weeks |
| DRUG | AD-2282 | PO, Once daily, 8weeks |
| DRUG | Placebo of AD-2282 | PO, Once daily, 8weeks |
Timeline
- Start date
- 2025-02-01
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
- First posted
- 2024-12-24
- Last updated
- 2025-02-04
Source: ClinicalTrials.gov record NCT06747936. Inclusion in this directory is not an endorsement.